semaglutide 2.5mg Oral Wegovy approved for obesity management by FDA on December 23, 2025 Formulation: High‑dose oral (25 mg daily) — previously only available as weekly injections. Indication: Adults with obesity (BMI ≥30) This medication is used with a doctor An Ongoing Crisis: Semaglutide Shortage

Over the last decade, more than 200 drug applications have received refuse-to-file notifications, with an average delay of over a year before resubmission

Challenges and Future Perspectives While the research on IGF-1 LR3 is promising, several challenges remain

casei had the greatest efficacy in treating pediatric atopic dermatitis [5]

Conner Mertens 09:30 Looking back, and we all know hindsight is 2020, but what did we learn from the COVID vaccines that we can apply to the treatments to it to make it better, more accessible, etc, etc

How do GLP-1 medications affect fluid balance

Reduction in exacerbations due to NAC also has a dose response effect and the risk of hospital readmissions is seen to reduce gradually and significantly with increasing doses of NAC (27)